VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

Anna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, Marica Eoli, Donata Bianchessi, Francesco Pasqualetti, Patrizia Farina, Stefania Cuzzubbo, Jaime Gallego-Perez-Larraya, Blandine Boisselier, Francois Ducray, Caroline Cheneau, Arrigo Moglia, Gaetano Finocchiaro, Yannick Marie, Amithys Rahimian, Khe Hoang-Xuan, Jean Yves Delattre, Karima Mokhtari, Marc Sanson

Research output: Contribution to journalArticlepeer-review


Although anti-VEGF therapy is widely used in high-grade gliomas, no predictor of response or toxicity has been reported yet. We investigated here the association of the functional single nucleotide polymorphism (SNP) rs2010963, located in the 5′ untranslated terminal region of the VEGFA gene, with survival, response to bevacizumab (BVZ) and vascular toxicity. The rs2010963 was genotyped by Taqman assay in blood DNA from 954 glioma patients with available survival data, including 225 glioblastoma (GBM) patients treated with BVZ. VEGFA plasma levels were assessed by ELISA in 87 patients before treatment. Thrombo-hemorragic adverse events were recorded during BVZ treatment or not, and in an independent population of 92 GBM patients treated with temozolomide. The CC genotype was associated with the occurrence of thrombo-hemorragic events (CC 25 versus CG 13.5 and GG 5.2 %; P = 0.0044) during BVZ. A similar but weaker and non significant trend was observed in patients not receiving BVZ. A CC genotype was associated with higher levels of plasma VEGFA at baseline (107.6 versus 57.50 pg/mL in heterozygotes (CG) and 52.75 pg/mL in GG patients, P = 0.035 and P = 0.028 respectively). The CC genotype tended to be associated to longer PFS when treated with BVZ (P = 0.05), but not when treated with the temozolomide treatment. Our data suggest that the rs2010963 genotype is associated with longer PFS, higher risk of vascular events in recurrent GBM especially treated with BVZ, and higher plasma VEGFA concentration. It may help to identify patients at risk of vascular adverse events during BVZ treatment.

Original languageEnglish
Pages (from-to)499-504
Number of pages6
JournalJournal of Neuro-Oncology
Issue number3
Publication statusPublished - 2015


  • Bevacizumab
  • Glioblastoma
  • rs2010963
  • SNP
  • VEGF

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab'. Together they form a unique fingerprint.

Cite this